Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Views & Analysis 2016 saw slump in FDA drug approvals, but 2017 could be retu... FDA approvals could rebound in 2017 - but concerns about big pharma R&D productivity won't go away.
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
Articles 10 drugs – and their prices – which changed pharma in 2015 In a record-breaking year for pharma, which drugs were the most outstanding?
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
